May 19th, 2011, by David Pascoe | galderma, new treatments, sansrosa
News today of a parallel Sansrosa Phase III Trial. This just announced trial is shorter than the Long Term (52 week) Safety Trial, and seeks to confirm that Sansrosa Gel (CD07805/47) is more effective than the inactive vehicle gel and is itself a safe treatment. Trial ID: NCT01355458 (seems to be somewhat duplicated with NCT01355471) …
March 20th, 2011, by David Pascoe | galderma, new treatments, sansrosa
News today that Galderma has listed CD07805/47 as entering large scale Phase III trials. Under the previous owners of the Brimonidine-based technology Collagenex, the product then known as Sansrosa …
January 19th, 2011, by David Pascoe | galderma, sansrosa
The path from the laboratory for Sansrosa / COL-118 / CD07805/47 to a product that realises the promise of permanently reducing a red face has been a long one. We first heard about a product …
September 1st, 2010, by David Pascoe | clinical trials, new treatments, sansrosa
The recruiting manager from Frontage Clinical is looking for participants in the trial they are hosting for rosacea redness. Frontage Clinical in Hackensack, NJ is conducting a research study to evaluate the safety of an investigational topical gel medication for moderate to severe facial redness associated with ROSACEA. All qualified participants will receive at no cost …
August 4th, 2010, by David Pascoe | galderma, sansrosa
In yet more proof that Galderma wants to sit on the drug known as Sansrosa, a new August 2010 Phase II dose finding study has been listed at clinicaltrials.gov. This latest trial will compare Sansrosa, or CD07805/47 as Galderma now calls it, in strengths of 0.5% and 0.18% against a placebo containing just the vehicle gel. A total of 260 patients will be …
